Sera Prognostics, Inc. Stock price

Equities

SERA

US81749D1072

Business Support Services

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
8.96 USD -3.24% Intraday chart for Sera Prognostics, Inc. -2.93% +49.83%
Sales 2023 * 350K Sales 2024 * 2.3M Capitalization 281M
Net income 2023 * -36M Net income 2024 * -31M EV / Sales 2023 * 802 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 122 x
P/E ratio 2023 *
-7.66 x
P/E ratio 2024 *
-8.83 x
Employees 88
Yield 2023 *
-
Yield 2024 *
-
Free-Float 77.68%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.24%
1 week-2.93%
Current month+0.45%
1 month-7.72%
3 months+50.34%
6 months+412.00%
Current year+49.83%
More quotes
1 week
8.60
Extreme 8.6
9.48
1 month
8.25
Extreme 8.25
10.44
Current year
4.90
Extreme 4.9
10.44
1 year
1.52
Extreme 1.52
10.44
3 years
1.10
Extreme 1.1
15.50
5 years
1.10
Extreme 1.1
15.50
10 years
1.10
Extreme 1.1
15.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 21-11-07
Director of Finance/CFO 37 17-06-30
Chief Tech/Sci/R&D Officer 62 11-10-31
Members of the board TitleAgeSince
Director/Board Member 66 21-11-28
Director/Board Member 72 10-07-31
Chairman 56 11-10-31
More insiders
Date Price Change Volume
24-03-18 8.96 -3.24% 88,260
24-03-15 9.26 +3.58% 146,396
24-03-14 8.94 -2.30% 58,693
24-03-13 9.15 0.00% 57,445
24-03-12 9.15 -0.87% 114,788

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Sera Prognostics, Inc. is a women's health diagnostic company that is focused on utilizing its proteomics and bioinformatics platform to discover, develop, and commercialize clinically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The Company's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman carrying a single fetus during weeks 18 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth, and postpartum depression.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
8.96
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock Sera Prognostics, Inc. - Nasdaq